BSE Live
Oct 01, 16:01Prev. Close
5422.20
Open Price
5416.20
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
NSE Live
Oct 01, 15:54Prev. Close
5425.00
Open Price
5392.00
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
0.00 (0)
Balance Sheet of Alkem Laboratories (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
EQUITIES AND LIABILITIES | ||||||
SHAREHOLDER'S FUNDS | ||||||
Equity Share Capital | 23.91 | 23.91 | 23.91 | 23.91 | 23.91 | |
Total Share Capital | 23.91 | 23.91 | 23.91 | 23.91 | 23.91 | |
Reserves and Surplus | 11,960.96 | 10,268.61 | 9,021.38 | 8,613.99 | 7,351.70 | |
Total Reserves and Surplus | 11,960.96 | 10,268.61 | 9,021.38 | 8,613.99 | 7,351.70 | |
Total Shareholders Funds | 11,984.87 | 10,312.06 | 9,045.29 | 8,637.90 | 7,376.73 | |
Minority Interest | 448.76 | 402.34 | 389.71 | 209.43 | 181.28 | |
NON-CURRENT LIABILITIES | ||||||
Long Term Borrowings | 310.91 | 40.00 | 0.00 | 9.38 | 34.25 | |
Deferred Tax Liabilities [Net] | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Other Long Term Liabilities | 643.36 | 526.09 | 245.14 | 74.39 | 72.22 | |
Long Term Provisions | 338.22 | 299.86 | 369.36 | 332.75 | 250.73 | |
Total Non-Current Liabilities | 1,292.49 | 865.95 | 614.50 | 416.52 | 357.20 | |
CURRENT LIABILITIES | ||||||
Short Term Borrowings | 751.88 | 1,173.97 | 1,307.15 | 2,570.74 | 1,635.96 | |
Trade Payables | 1,839.35 | 1,748.12 | 1,165.03 | 1,173.38 | 1,069.41 | |
Other Current Liabilities | 1,214.64 | 945.59 | 862.22 | 787.62 | 662.04 | |
Short Term Provisions | 159.11 | 126.87 | 372.75 | 273.60 | 236.64 | |
Total Current Liabilities | 3,964.98 | 3,994.55 | 3,707.15 | 4,805.34 | 3,604.05 | |
Total Capital And Liabilities | 17,691.10 | 15,574.90 | 13,756.65 | 14,069.19 | 11,519.26 | |
ASSETS | ||||||
NON-CURRENT ASSETS | ||||||
Tangible Assets | 2,386.15 | 2,408.63 | 2,203.25 | 2,287.10 | 2,233.93 | |
Intangible Assets | 43.05 | 47.41 | 66.41 | 211.54 | 163.66 | |
Capital Work-In-Progress | 476.55 | 148.40 | 310.27 | 339.48 | 393.28 | |
Fixed Assets | 2,977.27 | 2,614.61 | 2,592.90 | 2,838.12 | 2,790.87 | |
Non-Current Investments | 943.24 | 334.80 | 304.61 | 231.67 | 153.95 | |
Deferred Tax Assets [Net] | 1,738.25 | 1,514.83 | 1,302.50 | 1,309.26 | 1,107.91 | |
Long Term Loans And Advances | 0.00 | 0.00 | 8.02 | 8.02 | 11.04 | |
Other Non-Current Assets | 663.41 | 282.34 | 405.75 | 843.60 | 131.28 | |
Total Non-Current Assets | 6,745.28 | 5,163.32 | 5,026.95 | 5,633.76 | 4,590.44 | |
CURRENT ASSETS | ||||||
Current Investments | 902.26 | 148.99 | 317.21 | 139.31 | 178.83 | |
Inventories | 2,922.41 | 2,661.18 | 2,607.53 | 3,005.53 | 2,312.44 | |
Trade Receivables | 2,466.25 | 2,252.81 | 2,132.18 | 1,884.60 | 1,607.21 | |
Cash And Cash Equivalents | 1,563.08 | 1,579.35 | 2,616.89 | 2,578.58 | 1,990.45 | |
Short Term Loans And Advances | 9.04 | 9.07 | 6.77 | 20.25 | 31.22 | |
OtherCurrentAssets | 3,082.78 | 3,760.18 | 1,049.12 | 807.16 | 808.67 | |
Total Current Assets | 10,945.82 | 10,411.58 | 8,729.70 | 8,435.43 | 6,928.82 | |
Total Assets | 17,691.10 | 15,574.90 | 13,756.65 | 14,069.19 | 11,519.26 | |
OTHER ADDITIONAL INFORMATION | ||||||
CONTINGENT LIABILITIES, COMMITMENTS | ||||||
Contingent Liabilities | 995.22 | 210.67 | 410.26 | 425.90 | 449.06 | |
BONUS DETAILS | ||||||
Bonus Equity Share Capital | 11.96 | 11.96 | 11.96 | 11.96 | 11.96 | |
NON-CURRENT INVESTMENTS | ||||||
Non-Current Investments Quoted Market Value | 710.39 | 170.40 | 142.67 | 0.00 | 0.00 | |
Non-Current Investments Unquoted Book Value | 200.47 | 164.40 | 161.94 | 126.59 | 98.40 | |
CURRENT INVESTMENTS | ||||||
Current Investments Quoted Market Value | 827.56 | 46.92 | 212.14 | 0.00 | 0.00 | |
Current Investments Unquoted Book Value | 74.70 | 102.07 | 105.06 | 0.00 | 144.83 |
29.09.2025
23.09.2025
19.09.2025
10.09.2025
Alkem Lab Standalone June 2025 Net Sales at Rs 2,372.17 crore, down 5.12% Y-o-Y
10.09.2025
Alkem Lab Standalone June 2025 Net Sales at Rs 2,372.17 crore, down 5.12% Y-o-Y
12.08.2025
Q1 Results impact: Alkem Labs, PN Gadgil shares rally up to 10% on strong earnings, Granules up 4%
12.06.2025
Alkem Lab Standalone March 2025 Net Sales at Rs 2,044.94 crore, down 13.55% Y-o-Y
05.06.2025
Alkem Lab Consolidated March 2025 Net Sales at Rs 3,143.75 crore, up 7.08% Y-o-Y
12.07.2023
Alkem Laboratories Q1 PAT seen up 135.1% YoY to Rs 299.7 cr: Nirmal Bang
17.10.2018
Alkem Labs Q2 PAT may dip 30.2% YoY to Rs. 220 cr: HDFC Securities
20.04.2018
Alkem Labs Q4 PAT may dip 1.5% YoY to Rs. 130 cr: HDFC Securities
12.04.2018
Pharma Q4 earnings preview: Tough quarter; US pricing pressure, domestic sales recovery hold key